drugset / Trial / NCT04917523
Immuno-bridging Study of Inactivated SARS-CoV-2 Vaccine in Healthy Population Aged 3-17 vs Aged 18 Years Old and Above
Phase 3
Completed
1800 enrolled
China National Biotec Group Company Limited
Beijing Institute of Biological Products Co Ltd. · collab
RandomizedParallel-groupOpen-labelPrevention
Summary
This is a open label clinical trial to evaluate the efficacy, safety and immunogenicity of inactivated SARS-CoV-2 vaccines (Vero cell) in healthy people aged 3-17 years old in comparison with healthy population aged 18 years old and above
Timeline
- Start
- 2021-07-02
- Primary completion
- 2022-03-31
- Completion
- 2022-04-29
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Inactivated SARS-CoV-2 vaccine (Vero cell) | Vaccine | 0.5 ml | Intramuscular |